Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) FCF Margin (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed FCF Margin for 10 consecutive years, with 48.61% as the latest value for Q4 2025.

  • On a quarterly basis, FCF Margin fell 34.0% to 48.61% in Q4 2025 year-over-year; TTM through Dec 2025 was 70.13%, a 504.0% increase, with the full-year FY2025 number at 70.13%, up 504.0% from a year prior.
  • FCF Margin was 48.61% for Q4 2025 at Ultragenyx Pharmaceutical, up from 57.96% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 18.53% in Q4 2022 to a low of 178.03% in Q3 2022.
  • A 5-year average of 96.95% and a median of 91.36% in 2021 define the central range for FCF Margin.
  • Biggest YoY gain for FCF Margin was 12405bps in 2021; the steepest drop was -23316bps in 2021.
  • Ultragenyx Pharmaceutical's FCF Margin stood at 19.54% in 2021, then increased by 5bps to 18.53% in 2022, then tumbled by -118bps to 40.45% in 2023, then dropped by -19bps to 48.27% in 2024, then dropped by -1bps to 48.61% in 2025.
  • Per Business Quant, the three most recent readings for RARE's FCF Margin are 48.61% (Q4 2025), 57.96% (Q3 2025), and 66.36% (Q2 2025).